Cycloset is first diabetes drug to clear US CV safety hurdle
07 May 2009
Sue Sutter
VeroScience/S2 Therapeutics' Cycloset (bromocriptine mesylate) has become the first new type 2 diabetes therapy to win US
FDA licensing since the agency imposed stricter cardiovascular safety requirements for such drugs late last year.
The agency approved Cycloset, a fast-acting...
Please Login to read the full article.